Cancer Targeting Therapies
Conventional and Advanced Perspectives
Herausgeber: Ali, Muhammad Yasir; Bukhari, Shazia
Cancer Targeting Therapies
Conventional and Advanced Perspectives
Herausgeber: Ali, Muhammad Yasir; Bukhari, Shazia
- Broschiertes Buch
- Merkliste
- Auf die Merkliste
- Bewerten Bewerten
- Teilen
- Produkt teilen
- Produkterinnerung
- Produkterinnerung
This volume in the popular series, Drugs and the Pharmaceutical Sciences, begins with the history of cancer treatment, carcinogens, and molecular mechanisms involved in cancer pathogenesis.
This volume in the popular series, Drugs and the Pharmaceutical Sciences, begins with the history of cancer treatment, carcinogens, and molecular mechanisms involved in cancer pathogenesis.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Produktdetails
- Produktdetails
- Verlag: CRC Press
- Seitenzahl: 296
- Erscheinungstermin: 19. Dezember 2024
- Englisch
- Abmessung: 254mm x 178mm x 17mm
- Gewicht: 549g
- ISBN-13: 9781032427126
- ISBN-10: 1032427124
- Artikelnr.: 72110017
- Herstellerkennzeichnung
- Libri GmbH
- Europaallee 1
- 36244 Bad Hersfeld
- 06621 890
- Verlag: CRC Press
- Seitenzahl: 296
- Erscheinungstermin: 19. Dezember 2024
- Englisch
- Abmessung: 254mm x 178mm x 17mm
- Gewicht: 549g
- ISBN-13: 9781032427126
- ISBN-10: 1032427124
- Artikelnr.: 72110017
- Herstellerkennzeichnung
- Libri GmbH
- Europaallee 1
- 36244 Bad Hersfeld
- 06621 890
Dr. Muhammad Yasir Ali My pharmacy career started back in 2002 as a graduate student, leading to the achievement of a graduate and then a master's degree in Pharmaceutical Technology in 2009. Nevertheless, with my thirst for knowledge as a student and researcher, an in-line experience in production and quality control in Roche Pakistan helped me in knowing the ropes of the subject. Later on, I joined the university of Lahore as a faculty member and taught different courses to pharmacy graduates, especially pharmaceutical technology. In 2011 after joining my current job, I kept on teaching and indulged myself in research which is still going on, meanwhile, I got my doctorate (Pharmaceutical Technology) from Germany. I have more than 30 research publications, one research project, practical application of pharmacy knowledge in the form of different marketed products, several book chapters, and one book as editor in my research basket. I got chances of presenting research papers and scientific lectures in different organizations in Germany, USA, UK, and Pakistan. Dr. Shazia Bukhari I completed my undergraduate studies from the Bahuddin Zakariya University, Multan (1998-2001) and my M.Phil. studies from the Department of Biochemistry, University of Agriculture, Faisalabad Pakistan (2001-2003). Then I continued higher studies in Punjab University and earned Ph.D. degree in Biochemistry (2005-2009). I started my career at Hi-Tech Lab, University of Agriculture, Faisalabad (2003 - 2004). Then I joined Center for Agricultural Biochemistry and Biotechnology (CABB), University of Agriculture, Faisalabad as Research Officer/Lecturer (2004-2011). Then I joined Government College University as Assistant Professor (2011-2014). I was promoted to Associate Professor (2014-2019 and Professor (2019 to date) in the Department of Biochemistry of the same university. My research interest focuses on the exploration of indigenous flora for treatment of various diseases, based on an understanding of the mechanisms underlying the successful interactions between the plant components and disease. For this purpose, we are now using computational tools to correlate the laboratory findings with computer modeling. I am also working to enhance resistance of wheat (Triticum aestivum) against fungus diseases like rust. For this purpose, we have been transforming rust resistance and Pathogenesis-Related genes, isolated from local verities, and transform into high yielding wheat commercial varieties. I have screened and characterized nine novel genes relating rust resistance and pathogenesis related and deposited in gene bank. I am currently running two projects for achieving this goal approved by HEC: 3.679,655 million) as PI and 2nd approved by Technology Development Funds. HEC (13.609 million) as PI.
1. History of Cancer Therapies
2. Cancer and Carcinogens
3. Causes of Death from Cancer
4. Passive Targeting
5. Cancer Active Targeting Strategies
Conventional Cancer Therapies
6. Oral Anticancer Therapies
7. Parenteral Anticancer Therapies
Advanced Cancer Therapies
8. The Advent of Micro and Nano-spheres for Cancer Treatment
9. The Emergence of Liposomes in Cancer Therapy
10. Niosomes-Based Anticancer Therapies
11. Solid Lipid Nanoparticles-Based Anticancer Therapies
12. Mesoporous Nanoparticles-Based Anticancer Therapies
13. Antibody-Based Cancer Therapies
14. Aptamer-Based Anticancer Therapies
15. Polyamidoamines-Based Anticancer Therapies
16. Photodynamic Therapies for Cancer Treatment
2. Cancer and Carcinogens
3. Causes of Death from Cancer
4. Passive Targeting
5. Cancer Active Targeting Strategies
Conventional Cancer Therapies
6. Oral Anticancer Therapies
7. Parenteral Anticancer Therapies
Advanced Cancer Therapies
8. The Advent of Micro and Nano-spheres for Cancer Treatment
9. The Emergence of Liposomes in Cancer Therapy
10. Niosomes-Based Anticancer Therapies
11. Solid Lipid Nanoparticles-Based Anticancer Therapies
12. Mesoporous Nanoparticles-Based Anticancer Therapies
13. Antibody-Based Cancer Therapies
14. Aptamer-Based Anticancer Therapies
15. Polyamidoamines-Based Anticancer Therapies
16. Photodynamic Therapies for Cancer Treatment
1. History of Cancer Therapies
2. Cancer and Carcinogens
3. Causes of Death from Cancer
4. Passive Targeting
5. Cancer Active Targeting Strategies
Conventional Cancer Therapies
6. Oral Anticancer Therapies
7. Parenteral Anticancer Therapies
Advanced Cancer Therapies
8. The Advent of Micro and Nano-spheres for Cancer Treatment
9. The Emergence of Liposomes in Cancer Therapy
10. Niosomes-Based Anticancer Therapies
11. Solid Lipid Nanoparticles-Based Anticancer Therapies
12. Mesoporous Nanoparticles-Based Anticancer Therapies
13. Antibody-Based Cancer Therapies
14. Aptamer-Based Anticancer Therapies
15. Polyamidoamines-Based Anticancer Therapies
16. Photodynamic Therapies for Cancer Treatment
2. Cancer and Carcinogens
3. Causes of Death from Cancer
4. Passive Targeting
5. Cancer Active Targeting Strategies
Conventional Cancer Therapies
6. Oral Anticancer Therapies
7. Parenteral Anticancer Therapies
Advanced Cancer Therapies
8. The Advent of Micro and Nano-spheres for Cancer Treatment
9. The Emergence of Liposomes in Cancer Therapy
10. Niosomes-Based Anticancer Therapies
11. Solid Lipid Nanoparticles-Based Anticancer Therapies
12. Mesoporous Nanoparticles-Based Anticancer Therapies
13. Antibody-Based Cancer Therapies
14. Aptamer-Based Anticancer Therapies
15. Polyamidoamines-Based Anticancer Therapies
16. Photodynamic Therapies for Cancer Treatment